

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: M. Rigdon Lentz

Serial No.: 09/699,003

Art Unit: 3761

Filed: October 26, 2000

Examiner: Leslie R. Deak

For: *METHOD AND COMPOSITIONS FOR TREATMENT OF CANCERS*

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL STATEMENT UNDER MPEP § 2001.06(c)

Further to the Statement under MPEP § 2001.06(c) filed on July 9, 2008, Applicant provides the following additional information.

A related case, U.S.S.N. 09/709,045 was involved in an interference No. 105,413 with U.S. Patent No. 6,379,708 to Howell, et al. Allegations were made by Howell that the Lentz application was invalid under 35 U.S.C. 102, 103, 112, improper inventorship and for inequitable conduct. The Board of Patent Appeals and Interferences ultimately held in Lentz' favor on all of these issues.

The assignees of the '708 patent to Howell, then filed an action under 35 U.S.C. 146 in the U.S. District Court, District of Columbia, Cytologic, Inc. and Colorado State University Research Foundation v. BioPheresis GMBH and BioPheresis Technologies, Inc. 1:08-cv-00978-CKK.

U.S.S.N.: 09/699,003
Filed: October 26, 2000
STATEMENT UNDER
MPEP § 2001.06(c)

A motion is pending in the U.S. District Court that the Board of Patent Appeals and Interferences improperly declared the interference on the grounds that the claims were not exactly copied within one year.

Additionally, Applicant draws the Examiner's attention to the Supplemental Information Disclosure Statements filed on October 17, 2007, on March 27, 2008, and March 9, 2009, after a Notice of Allowance was issued and then withdrawn by the Examiner on December 17, 2007, in this application. After the filing of the Supplemental Information Statements it was recognized that some of the cited references may have been known to the Applicant, the undersigned, or the assignee more than three months prior to the filing of the Supplemental Information Disclosure Statements. Any certification under 37 C.F.R. 1.97 should therefore be considered to be withdrawn.

It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge the fee to Deposit Account No. 50-3129.

Respectfully submitted,

/Patrea L. Pabst/
Patrea L. Pabst
Reg. No. 31,284

Dated: July 2, 2009

PABST PATENT GROUP LLP
1545 Peachtree Street, Suite 320
Atlanta, Georgia 30309
(404) 879-2151 (Telephone)
(404) 879-2160 (Fax)